Business Context and Reporting Period
Company: CVS Corporation (now CVS Health Corp)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended January 1, 2005 (52 weeks)
Business Overview: CVS is the largest retail drugstore chain in the U.S., operating 5,375 stores across 36 states and D.C. Operations are divided into Retail Pharmacy (94% of net sales) and Pharmacy Benefit Management (PBM), which covers approximately 30 million lives. A major strategic event in 2004 was the acquisition of 1,268 Eckerd drugstores and related PBM assets from J.C. Penney on July 31, 2004.
Key Financial Metrics
| Metric | 2004 (52 weeks) | 2003 (53 weeks) |
|---|---|---|
| Net Sales | $30,594.3 million | $26,588.0 million |
| Gross Margin | $8,031.2 million | $6,863.0 million |
| Operating Profit | $1,454.7 million | $1,423.6 million |
| Net Earnings | $918.8 million | $847.3 million |
| Diluted EPS | $2.20 | $2.06 |
| Total Assets | $14,546.8 million | $10,543.1 million |
| Long-term Debt | $1,925.9 million | $753.1 million |
| Shareholders' Equity | $6,987.2 million | $6,021.8 million |
Note: Cash flow statement details are incorporated by reference and not explicitly detailed in the provided text, though the company funds growth through operations, sale-leasebacks, and borrowings.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 15.1% to $30.6 billion, driven primarily by the acquisition of Eckerd assets and organic growth in pharmacy sales (which now represent 70% of total sales).
- Store Count: Total store count rose from 4,179 to 5,375, a 28.6% increase, largely due to the acquisition of 1,268 Eckerd stores.
- Debt Levels: Long-term debt increased significantly from $753.1 million to $1.93 billion to finance the Eckerd acquisition and subsequent refinancing.
- Accounting Adjustments: In 2004, the company recorded a non-cash pre-tax adjustment of $9.0 million to SG&A and $56.9 million to depreciation/amortization to conform lease accounting to SEC views. Additionally, a $60.0 million reversal of tax reserves reduced the income tax provision.
Guidance, Outlook, and Risks
Outlook and Strategy
- Store Development: CVS expects to open approximately 275-300 new or relocated stores in 2005.
- Dividends: The Board authorized a 9% dividend increase to $0.0725 per share for Q1 2005 ($0.29 annualized).
- Market Trends: Management cites an aging population, increased pharmaceutical usage, and the upcoming Medicare Part D benefit (2006) as favorable industry trends.
Risks and Contingencies
- Legal Proceedings:
- Securities Litigation: A class action alleging securities fraud (In re CVS Corporation Securities Litigation) is set for trial on May 9, 2005. The company intends to defend vigorously.
- ERISA Action: A class action regarding the 401(k) plan filed in October 2004.
- Government Investigations: Ongoing investigations by the Rhode Island Attorney General and the U.S. Department of Justice regarding generic drug dispensing practices and business relationships with state legislators.
- Market Risk: The company manages interest rate risk via Treasury-Lock Contracts; as of Jan 1, 2005, no derivative instruments were in place, and exposure is deemed not material.
Investor Verification Checklist
- Integration of Eckerd: Verify the progress of converting 1,268 acquired Eckerd stores to CVS systems and the completion of planned remodels (targeted for July 2005).
- Legal Exposure: Monitor the outcome of the securities fraud trial scheduled for May 2005 and the status of DOJ investigations into generic drug reimbursement practices.
- Debt Servicing: Review the impact of the increased long-term debt ($1.93B) on future interest expenses and liquidity, particularly given the refinancing of short-term borrowings.
- Accounting Changes: Confirm the long-term impact of the 2004 lease accounting adjustments on future depreciation and SG&A expenses.
- Medicare Part D: Assess the company's preparedness and strategic positioning for the 2006 implementation of the federal prescription drug benefit.